Free Newsletter
Six die after Chinese antibody injections
Just as the heparin hoopla was starting to settle down, now China is reporting that six patients in Jiangxi province have died after injections of immunoglobulins. All the injections came from a single batch made by Jiangxi Yabo Bio-Pharmaceutical, which has been ordered to stop producing the drug. China's State Food and Drug Administration has launched an investigation. Penalties for pharma-tampering are severe in China; last month, five officials of a company that sold a tainted antibiotic were sentenced to seven years in prison.
- read the AFP story
- check out the Associated Press article
Related Articles:
U.S., China trade blame on heparin
China launches drug recall system
China to overhaul drug safety regulations
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: